JPWO2019229153A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019229153A5 JPWO2019229153A5 JP2020566627A JP2020566627A JPWO2019229153A5 JP WO2019229153 A5 JPWO2019229153 A5 JP WO2019229153A5 JP 2020566627 A JP2020566627 A JP 2020566627A JP 2020566627 A JP2020566627 A JP 2020566627A JP WO2019229153 A5 JPWO2019229153 A5 JP WO2019229153A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic product
- composition according
- pharmaceutical composition
- disease
- allergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000027866 inflammatory disease Diseases 0.000 claims 8
- 239000004971 Cross linker Substances 0.000 claims 7
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 5
- 208000010668 atopic eczema Diseases 0.000 claims 5
- 230000000172 allergic effect Effects 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010048768 Dermatosis Diseases 0.000 claims 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000024376 chronic urticaria Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 238000000586 desensitisation Methods 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010001742 Allergy to animal Diseases 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000003843 mucus production Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960002317 succinimide Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023092544A JP2023110045A (ja) | 2018-05-29 | 2023-06-05 | 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677290P | 2018-05-29 | 2018-05-29 | |
| EP18305651.4A EP3574915A1 (en) | 2018-05-29 | 2018-05-29 | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| EP18305651.4 | 2018-05-29 | ||
| US62/677,290 | 2018-05-29 | ||
| EPPCT/EP2019/050154 | 2019-01-04 | ||
| PCT/EP2019/050154 WO2019228674A1 (en) | 2018-05-29 | 2019-01-04 | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il-13 expression or activity |
| PCT/EP2019/064025 WO2019229153A2 (en) | 2018-05-29 | 2019-05-29 | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092544A Division JP2023110045A (ja) | 2018-05-29 | 2023-06-05 | 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525726A JP2021525726A (ja) | 2021-09-27 |
| JP2021525726A5 JP2021525726A5 (https=) | 2022-06-03 |
| JPWO2019229153A5 true JPWO2019229153A5 (https=) | 2022-06-03 |
| JP7291729B2 JP7291729B2 (ja) | 2023-06-15 |
Family
ID=62631036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566627A Active JP7291729B2 (ja) | 2018-05-29 | 2019-05-29 | 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物 |
| JP2023092544A Pending JP2023110045A (ja) | 2018-05-29 | 2023-06-05 | 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092544A Pending JP2023110045A (ja) | 2018-05-29 | 2023-06-05 | 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12059457B2 (https=) |
| EP (3) | EP3574915A1 (https=) |
| JP (2) | JP7291729B2 (https=) |
| KR (2) | KR102871378B1 (https=) |
| CN (1) | CN112423784B (https=) |
| AU (2) | AU2019276173B2 (https=) |
| BR (1) | BR112020024308A2 (https=) |
| CA (1) | CA3101702A1 (https=) |
| CU (1) | CU20200091A7 (https=) |
| IL (2) | IL278898B2 (https=) |
| MA (1) | MA52748A (https=) |
| MX (2) | MX421649B (https=) |
| SG (1) | SG11202011528UA (https=) |
| WO (2) | WO2019228674A1 (https=) |
| ZA (1) | ZA202007264B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| EP3845556A1 (fr) * | 2019-12-31 | 2021-07-07 | Peptinov SAS | Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6 |
| WO2023021195A1 (en) * | 2021-08-20 | 2023-02-23 | Neovacs | mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US646A (en) | 1838-03-21 | Improvement in furnaces for smelting iron with anthracite | ||
| US6207A (en) | 1849-03-20 | Improved spriing snap-hook | ||
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| ATE378066T1 (de) | 1998-09-30 | 2007-11-15 | Wyeth Corp | Mutiertes cholera holotoxin als hilfsmittel |
| KR100898648B1 (ko) | 2001-06-07 | 2009-05-22 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
| CA2449670A1 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| WO2003040164A2 (en) | 2001-11-07 | 2003-05-15 | Cytos Biotechnology Ag | Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases |
| JP2006503017A (ja) | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用 |
| JP2006503018A (ja) * | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | ワクチン |
| EP1947116B1 (en) | 2003-02-10 | 2017-06-21 | 2-BBB Medicines B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| CA2562642A1 (en) * | 2004-04-13 | 2005-11-03 | Alza Corporation | Apparatus and method for transdermal delivery of multiple vaccines |
| US20070224205A1 (en) * | 2006-03-07 | 2007-09-27 | Powell Thomas J | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| CN100558747C (zh) * | 2006-04-06 | 2009-11-11 | 海南天源康泽医药科技有限公司 | 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| MX2013011201A (es) | 2011-03-29 | 2013-12-16 | Immunogen Inc | Proceso para la elaboracion de conjugados de mejor homogeneidad. |
| CA2832260C (en) * | 2011-04-07 | 2021-06-22 | Neovacs | Method for treating ifnalpha related conditions |
| CA2835018C (en) * | 2011-05-04 | 2020-04-21 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
| CN102807621B (zh) * | 2011-06-01 | 2016-04-13 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
| EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| DE202013011988U1 (de) | 2012-05-15 | 2015-04-01 | Rajesh Shah | Entzündungshemmende Rezeptur |
| PL2668959T3 (pl) * | 2012-05-31 | 2015-04-30 | Innavirvax | Związki immunogenne zawierające peptyd HIV gp41 sprzężony z białkiem nośnikowym CRM197 |
| AR101455A1 (es) * | 2014-08-05 | 2016-12-21 | Glaxosmithkline Biologicals Sa | Molécula portadora |
| CN109890408A (zh) * | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
-
2018
- 2018-05-29 EP EP18305651.4A patent/EP3574915A1/en not_active Withdrawn
-
2019
- 2019-01-04 WO PCT/EP2019/050154 patent/WO2019228674A1/en not_active Ceased
- 2019-05-29 CU CU2020000091A patent/CU20200091A7/es unknown
- 2019-05-29 CN CN201980043613.4A patent/CN112423784B/zh active Active
- 2019-05-29 EP EP19729660.1A patent/EP3801603A2/en active Pending
- 2019-05-29 MA MA052748A patent/MA52748A/fr unknown
- 2019-05-29 CA CA3101702A patent/CA3101702A1/en active Pending
- 2019-05-29 MX MX2020012925A patent/MX421649B/es unknown
- 2019-05-29 IL IL278898A patent/IL278898B2/en unknown
- 2019-05-29 KR KR1020207036154A patent/KR102871378B1/ko active Active
- 2019-05-29 IL IL309932A patent/IL309932A/en unknown
- 2019-05-29 US US17/058,318 patent/US12059457B2/en active Active
- 2019-05-29 SG SG11202011528UA patent/SG11202011528UA/en unknown
- 2019-05-29 AU AU2019276173A patent/AU2019276173B2/en active Active
- 2019-05-29 BR BR112020024308-6A patent/BR112020024308A2/pt unknown
- 2019-05-29 JP JP2020566627A patent/JP7291729B2/ja active Active
- 2019-05-29 WO PCT/EP2019/064025 patent/WO2019229153A2/en not_active Ceased
- 2019-05-29 KR KR1020257033788A patent/KR20250156179A/ko active Pending
- 2019-05-29 EP EP22185162.9A patent/EP4144366A1/en active Pending
-
2020
- 2020-11-20 ZA ZA2020/07264A patent/ZA202007264B/en unknown
- 2020-11-27 MX MX2024012944A patent/MX2024012944A/es unknown
-
2023
- 2023-06-05 JP JP2023092544A patent/JP2023110045A/ja active Pending
-
2024
- 2024-07-15 US US18/772,543 patent/US20250025541A1/en active Pending
-
2025
- 2025-06-02 AU AU2025204082A patent/AU2025204082A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525726A5 (https=) | ||
| EP1163212B1 (en) | Amide derivatives | |
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| JP6464384B2 (ja) | キナーゼ阻害剤 | |
| AU756292B2 (en) | Amide derivatives which are useful as cytokine inhibitors | |
| JP2020537657A (ja) | Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物 | |
| JPH08512041A (ja) | フルオルアルコキシ置換のベンズアミド及び環状ヌクレオチドホスホジエステラーゼ阻害剤としてのその使用 | |
| CN103130710B (zh) | 抗肠病毒71(ev71)己内酰胺醛类化合物及其制备方法和用途 | |
| JP2005523338A5 (https=) | ||
| JP2011509988A (ja) | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 | |
| CN110105348A (zh) | 新型迈克尔受体类肠病毒71型抑制剂的制备及用途 | |
| JPWO2019229153A5 (https=) | ||
| CN112057443A (zh) | 苯磺酰胺类化合物的医药用途及其药物组合物 | |
| AU2004251914A1 (en) | Diphenylpyridine derivatives, preparation and therapeutic application thereof | |
| Gulati et al. | Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases | |
| Van Scott et al. | Dust mite-induced asthma in cynomolgus monkeys | |
| CN102112441B (zh) | 吲哚衍生物作为nurr-1激活剂治疗帕金森病的用途 | |
| TW202432109A (zh) | 食慾素２型受體促效劑之給藥 | |
| CN108484550A (zh) | 一种含笑内酯衍生物及其制备方法和用途 | |
| JP2017514842A (ja) | 多形形態の［５−フルオロ−３−（｛２−［（４−フルオロベンゼン）スルホニル］ピリジン−３−イル｝メチル）−２−メチルインドール−１−イル］−酢酸 | |
| RU2020138620A (ru) | Иммуногенный продукт, содержащий il-4 и/или il-13 для лечения нарушений, ассоциированных с аберрантной экспрессией или активностью il-4 и/или il-13 | |
| RU2023132215A (ru) | Иммуногенный продукт, содержащий il-4 и/или il-13 для лечения нарушений, ассоциированных с аберрантной экспрессией или активностью il-4 и/или il-13 | |
| TW202535389A (zh) | Ｐｔｐｎ２／ｐｔｐ１ｂ降解劑及其治療方法 | |
| JP2021534110A5 (https=) | ||
| JPWO2023021195A5 (https=) |